IMMX Insider Trading
Insider Ownership Percentage: 55.40%
Insider Buying (Last 12 Months): $54,935.00
Insider Selling (Last 12 Months): $0.00
Immix Biopharma Share Price & Price History
Current Price: $2.41
Price Change: ▲ Price Increase of +0.32 (15.31%)
As of 05/22/2025 05:00 PM ET
Immix Biopharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2024 | Carey Ng | Director | Buy | 10,000 | $1.86 | $18,600.00 | 20,000 |  |
| 7/24/2024 | Jason Hsu | Director | Buy | 6,000 | $2.15 | $12,900.00 | 822,200 | |
| 7/18/2024 | Jason Hsu | Director | Buy | 3,200 | $2.07 | $6,624.00 | 816,200 | |
| 6/7/2024 | Gabriel S Morris | CFO | Buy | 2,500 | $2.12 | $5,300.00 | 285,834 | |
| 6/7/2024 | Ilya M Rachman | CEO | Buy | 2,600 | $2.13 | $5,538.00 | 1,136,259 | |
| 6/4/2024 | Gabriel S Morris | CFO | Buy | 3,300 | $1.81 | $5,973.00 | 283,334 | |
| 5/14/2024 | Gabriel S Morris | CFO | Buy | 4,500 | $2.23 | $10,035.00 | 85,816 | |
| 5/14/2024 | Ilya M Rachman | CEO | Buy | 4,300 | $2.25 | $9,675.00 | 912,000 | |
| 12/11/2023 | Jason Hsu | Director | Buy | 31,000 | $4.67 | $144,770.00 | 813,000 | |
| 12/8/2023 | Jason Hsu | Director | Buy | 25,000 | $4.88 | $122,000.00 | 782,000 | |
| 9/14/2023 | Carey Ng | Director | Buy | 10,000 | $2.58 | $25,800.00 | 10,000 | |
| 9/12/2023 | Helen C Adams | Director | Buy | 13,000 | $2.96 | $38,480.00 | 13,000 | |
| 9/7/2023 | Melissa Jane Buchan | Director | Buy | 20,000 | $2.46 | $49,200.00 | 20,000 | |
| 9/5/2023 | Magda Marquet | Director | Buy | 10,000 | $2.47 | $24,700.00 | 11,000 | |
| 8/31/2023 | Magda Marquet | Director | Buy | 1,000 | $2.01 | $2,010.00 | 1,000 | |
| 11/14/2022 | Ilya M Rachman | CEO | Buy | 5,200 | $1.00 | $5,200.00 | 907,700 | |
| 7/14/2022 | Sean Senn | Major Shareholder | Sell | 200 | $2.75 | $550.00 | 899,800 | |
Immix Biopharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2025 | Tocqueville Asset Management L.P. | 29,300 | $49K | 0.0% | -23.5% | 0.105% |  |
| 2/14/2025 | Jane Street Group LLC | 17,523 | $39K | 0.0% | N/A | 0.064% | |
| 2/6/2025 | SBI Securities Co. Ltd. | 17,500 | $38K | 0.0% | N/A | 0.064% | |
| 1/13/2025 | FNY Investment Advisers LLC | 28,750 | $63K | 0.0% | N/A | 0.105% | |
| 11/16/2024 | Geode Capital Management LLC | 150,082 | $0.22M | 0.0% | +5.6% | 0.546% | |
| 10/22/2024 | Private Advisor Group LLC | 34,325 | $51K | 0.0% | -47.3% | 0.130% | |
| 8/16/2024 | Invst LLC | 27,000 | $57K | 0.0% | N/A | 0.102% | |
| 8/12/2024 | XTX Topco Ltd | 17,663 | $35K | 0.0% | -66.2% | 0.067% | |
| 8/9/2024 | Renaissance Technologies LLC | 154,685 | $0.31M | 0.0% | -41.7% | 0.586% | |
| 8/7/2024 | AIGH Capital Management LLC | 1,406,680 | $2.79M | 0.9% | -9.5% | 5.326% | |
| 5/10/2024 | Tocqueville Asset Management L.P. | 37,800 | $0.12M | 0.0% | +89.0% | 0.143% | |
| 4/26/2024 | Tritonpoint Wealth LLC | 24,526 | $75K | 0.0% | N/A | 0.093% | |
| 2/7/2024 | Jump Financial LLC | 18,500 | $0.13M | 0.0% | N/A | 0.093% | |
| 2/6/2024 | Private Advisor Group LLC | 99,775 | $0.69M | 0.0% | N/A | 0.502% | |
| 2/1/2024 | OLD National Bancorp IN | 10,000 | $69K | 0.0% | N/A | 0.050% | |
| 1/30/2024 | Imprint Wealth LLC | 34,483 | $0.24M | 0.2% | +49.4% | 0.174% | |
| 11/9/2023 | Tocqueville Asset Management L.P. | 12,000 | $41K | 0.0% | N/A | 0.061% | |
| 10/23/2023 | Commonwealth Equity Services LLC | 28,855 | $99K | 0.0% | +26.4% | 0.147% | |
| 7/28/2023 | Koshinski Asset Management Inc. | 51,001 | $0.14M | 0.0% | N/A | 0.339% | |
| 7/25/2023 | UMB Bank n.a. | 72,639 | $0.20M | 0.0% | -26.8% | 0.483% | |
| 4/11/2023 | UMB Bank n.a. | 99,300 | $0.18M | 0.0% | N/A | 0.714% | |
| 2/10/2023 | Murchinson Ltd. | 67,200 | $0.15M | 0.0% | N/A | 0.482% | |
| 2/7/2023 | Lynwood Capital Management Inc. | 25,000 | $58K | 0.1% | N/A | 0.179% | |
| 2/1/2023 | Bank of Montreal Can | 15,000 | $36K | 0.0% | N/A | 0.108% | |
| 5/11/2022 | InterOcean Capital Group LLC | 15,900 | $38K | 0.0% | N/A | 0.115% | |
| 2/14/2022 | Altium Capital Management LP | 122,388 | $0.44M | 0.1% | N/A | 1.616% | |
| 2/14/2022 | Murchinson Ltd. | 695,600 | $2.48M | 0.2% | N/A | 9.183% | |
| 2/9/2022 | Context Capital Management LLC | 11,532 | $41K | 0.0% | N/A | 0.152% | |
| 2/2/2022 | PVG Asset Management Corp | 20,000 | $71K | 0.3% | N/A | 0.264% | |
| 2/1/2022 | Eidelman Virant Capital | 29,856 | $0.10M | 0.0% | N/A | 0.394% | |
Data available starting January 2016
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Read More on Immix Biopharma
Volume
3,883,331 shs
Average Volume
136,519 shs
Market Capitalization
$67.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.27
Who are the company insiders with the largest holdings of Immix Biopharma?
Who are the major institutional investors of Immix Biopharma?
Which major investors are selling Immix Biopharma stock?
During the previous quarter, IMMX stock was sold by these institutional investors:
- Tocqueville Asset Management L.P.
